- Home
- IMUX vs GNTA Comparison
IMUX vs GNTA Comparison
Compare IMUX & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- GNTA
- Stock Information
- Founded
- IMUX 2016
- GNTA 2014
- Country
- IMUX United States
- GNTA Italy
- Employees
- IMUX N/A
- GNTA N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMUX Health Care
- GNTA Health Care
- Exchange
- IMUX Nasdaq
- GNTA Nasdaq
- Market Cap
- IMUX 67.8M
- GNTA 81.2M
- IPO Year
- IMUX N/A
- GNTA 2021
- Fundamental
- Price
- IMUX $0.96
- GNTA $3.86
- Analyst Decision
- IMUX Strong Buy
- GNTA Strong Buy
- Analyst Count
- IMUX 5
- GNTA 1
- Target Price
- IMUX $7.50
- GNTA $25.00
- AVG Volume (30 Days)
- IMUX 1.1M
- GNTA 7.3K
- Earning Date
- IMUX 08-11-2025
- GNTA 01-01-0001
- Dividend Yield
- IMUX N/A
- GNTA N/A
- EPS Growth
- IMUX N/A
- GNTA N/A
- EPS
- IMUX N/A
- GNTA N/A
- Revenue
- IMUX N/A
- GNTA N/A
- Revenue This Year
- IMUX N/A
- GNTA N/A
- Revenue Next Year
- IMUX N/A
- GNTA N/A
- P/E Ratio
- IMUX N/A
- GNTA N/A
- Revenue Growth
- IMUX N/A
- GNTA N/A
- 52 Week Low
- IMUX $0.56
- GNTA $2.74
- 52 Week High
- IMUX $2.11
- GNTA $7.28
- Technical
- Relative Strength Index (RSI)
- IMUX 55.60
- GNTA 53.85
- Support Level
- IMUX $0.94
- GNTA $3.51
- Resistance Level
- IMUX $1.18
- GNTA $3.96
- Average True Range (ATR)
- IMUX 0.08
- GNTA 0.18
- MACD
- IMUX 0.01
- GNTA 0.01
- Stochastic Oscillator
- IMUX 40.95
- GNTA 71.43
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.